• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jean Philippe Lacour, MD; Christophe Perrin, MD; Isaac Bodokh, MD; Jean Paul Ortonne, MD
Department of Dermatology University of Nice 06002 Nice Cedex, France

Arch Dermatol. 1991;127(11):1732-1733.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Sclerodermaform infiltration of the skin with morpheaform and hyperpigmented patches is a frequent dermatologic manifestation of the eosinophilia-myalgia syndrome (EMS) related to levotryptophan use.^1,2 The prognosis of this syndrome is uncertain, because some cases progress despite discontinuation of levotryptophan use, and no treatment is known to regularly improve its symptoms, especially the dermatologic manifestations. The clinical and histologic sclerodermalike changes of this syndrome could cause dermatologists to test the action of drugs used in the treatment of scleroderma. We report a case of EMS with particularly severe sclerodermatous manifestations despite previous, simultaneous, and subsequent use of colchicine.

Report of a Case.—

A 66-year-old woman with a history of familial Mediterranean fever treated with colchicine (1 mg/d) was seen in January 1990 with a 6-month history of myalgias and skin symptoms. Pruritus, cutaneous burning sensations, and edematous infiltration of the abdomen and extremities appeared in . . . [Full Text PDF of this Article]

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?